TP-9201 data

TLIO (San Diego) announced Phase I findings of complete inhibition of platelet aggregation by TP-9201 without induction of abnormal bleeding times. Prolonged bleeding time was not reached until four-fold the minimally effective anti-aggregation dose.

The agent was given as a 2- to 24-hour infusion. Platelet function returned to normal 1-2 hours after discontinuing the infusion. Ongoing testing is adding increasing amounts by bolus injection to the infusion. ...